{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:35:43Z","timestamp":1765280143490},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00108-019-00699-7","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T13:02:34Z","timestamp":1574341354000},"page":"1251-1269","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemische Sklerose"],"prefix":"10.1007","volume":"60","author":[{"given":"Susanne","family":"Schinke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"699_CR1","volume-title":"EULAR textbook on systemic sclerosis","year":"2013","unstructured":"Hachulla\u00a0E, Czirjak\u00a0L (Hrsg) (2013) EULAR textbook on systemic sclerosis, 1.\u00a0Aufl. BMJ Publishing Group Ltd, London","edition":"1"},{"key":"699_CR2","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311:2490\u20132498","journal-title":"JAMA"},{"key":"699_CR3","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Scleroderma Lung Study Research Group, Tashkin\u00a0DP, Elashoff\u00a0R, Clements\u00a0PJ et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"699_CR4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semarthrit.2014.09.003","volume":"44","author":"M Iudici","year":"2015","unstructured":"Iudici\u00a0M, Cuomo\u00a0G, Vettori\u00a0S et al (2015) Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 44:437\u2013444","journal-title":"Semin Arthritis Rheum"},{"key":"699_CR5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.bor.0000434672.77891.41","volume":"25","author":"S Assassi","year":"2013","unstructured":"Assassi\u00a0S, Mayes\u00a0MD (2013) What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? Curr Opin Rheumatol 25:686\u2013691","journal-title":"Curr Opin Rheumatol"},{"key":"699_CR6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2010.137935","volume":"70","author":"MO Becker","year":"2011","unstructured":"Becker\u00a0MO, Br\u00fcckner\u00a0C, Scherer\u00a0HU et al (2011) The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 70:1340\u20131341","journal-title":"Ann Rheum Dis"},{"key":"699_CR7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","volume":"70","author":"G Riemekasten","year":"2011","unstructured":"Riemekasten\u00a0G, Philippe\u00a0A, N\u00e4ther\u00a0M et\u00a0al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70:530\u2013536","journal-title":"Ann Rheum Dis"},{"key":"699_CR8","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","volume":"16","author":"A Kill","year":"2014","unstructured":"Kill\u00a0A, Tabeling\u00a0C, Undeutsch\u00a0R et\u00a0al (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16:R29","journal-title":"Arthritis Res Ther"},{"key":"699_CR9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","volume":"190","author":"MO Becker","year":"2014","unstructured":"Becker\u00a0MO, Kill\u00a0A, Kutsche\u00a0M et\u00a0al (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190:808\u2013817","journal-title":"Am J Respir Crit Care Med"},{"key":"699_CR10","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","volume":"16","author":"J G\u00fcnther","year":"2014","unstructured":"G\u00fcnther\u00a0J, Kill\u00a0A, Becker\u00a0MO et al (2014) Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL\u20118 and CCL18 when stimulated by autoanti-bodies from systemic sclerosis patients. Arthritis Res Ther 16:R65","journal-title":"Arthritis Res Ther"},{"key":"699_CR11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","volume":"14","author":"D Giuggioli","year":"2015","unstructured":"Giuggioli\u00a0D, Lumetti\u00a0F, Colaci\u00a0M et\u00a0al (2015) Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 14:1072\u20131078","journal-title":"Autoimmun Rev"},{"key":"699_CR12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41927-018-0043-6","volume":"2","author":"SA Butt","year":"2018","unstructured":"Butt\u00a0SA et\u00a0al (2018) Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a\u00a0nationwide cohort study. BMC Rheumatol 2:36","journal-title":"BMC Rheumatol"},{"key":"699_CR13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/annrheumdis-2013-203618","volume":"73","author":"K Andr\u00e9asson","year":"2014","unstructured":"Andr\u00e9asson\u00a0K, Saxne\u00a0T, Bergknut\u00a0C et al (2014) Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 73:1788\u20131792","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"699_CR14","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig\u00a0M et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a\u00a0twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58(12):3902\u20133912","journal-title":"Arthritis Rheum"},{"issue":"supplement 2","key":"699_CR15","first-page":"A104","volume":"78","author":"S Bellando Randone","year":"2019","unstructured":"Bellando Randone\u00a0S et\u00a0al (2019) The very early diagnosis of systemic sclerosis (vedoss) project: predictors to develop definite disease from an international multicentre study. Ann Rheum Dis 78(supplement 2):A104","journal-title":"Ann Rheum Dis"},{"key":"699_CR16","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy\u00a0EC, Black\u00a0C, Fleischmajer\u00a0R et\u00a0al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J\u00a0Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"699_CR17","first-page":"70","volume":"48","author":"LG Hanitsch","year":"2009","unstructured":"Hanitsch\u00a0LG, Burmester\u00a0GR, Witt\u00a0C et\u00a0al (2009) Skin sclerosis is only of limited value to identify SSc patients with severe manifestations\u2014an analysis of a\u00a0distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Baillieres Clin Rheumatol 48:70\u201373","journal-title":"Baillieres Clin Rheumatol"},{"key":"699_CR18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen\u00a0F, Khanna\u00a0D, Fransen\u00a0J et\u00a0al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"699_CR19","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger\u00a0VK, Wirz\u00a0EG, Allanore\u00a0Y et\u00a0al (2016) Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE 11:e163894","journal-title":"PLoS ONE"},{"issue":"supplement 2","key":"699_CR20","first-page":"A198","volume":"78","author":"A-M Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold\u00a0A\u2011M (2019) Ann Rheum Dis 78(supplement 2):A198","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"699_CR21","doi-asserted-by":"crossref","first-page":"e000826","DOI":"10.1136\/rmdopen-2018-000826","volume":"5","author":"A-M Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold\u00a0A\u2011M et al (2019) Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a\u00a0Delphi-based expert consensus on core clinical features. RMD Open 5(1):e826","journal-title":"RMD Open"},{"key":"699_CR22","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","volume":"63","author":"M Humbert","year":"2011","unstructured":"Humbert\u00a0M, Yaici\u00a0A, de Groote\u00a0P et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:3522\u20133530","journal-title":"Arthritis Rheum"},{"key":"699_CR23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan\u00a0JG, Denton\u00a0CP, Gr\u00fcnig\u00a0E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340\u20131349","journal-title":"Ann Rheum Dis"},{"key":"699_CR24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","volume":"48","author":"I Marie","year":"2009","unstructured":"Marie\u00a0I et\u00a0al (2009) Rheumatology 48:1314\u20131319","journal-title":"Rheumatology"},{"issue":"8","key":"699_CR25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn\u00a0H et\u00a0al (2007) Scleroderma renal crisis: patient characteristics and long term outcomes. QJM 100(8):485\u2013494","journal-title":"QJM"},{"key":"699_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2017.10.001","volume":"452","author":"A Cerebelli","year":"2018","unstructured":"Cerebelli\u00a0A et\u00a0al (2018) J\u00a0Immunol Methods 452:1\u20135. https:\/\/doi.org\/10.1016\/j.jim.2017.10.001","journal-title":"J Immunol Methods"},{"issue":"4","key":"699_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41430-018-0116-z","volume":"72","author":"E Preis","year":"2018","unstructured":"Preis\u00a0E, Franz\u00a0K, Siegert\u00a0E et\u00a0al (2018) Eur J Clin Nutr 72(4):504\u2013510. https:\/\/doi.org\/10.1038\/s41430-018-0116-z","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"699_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40674-016-0038-7","volume":"2","author":"ND Morgan","year":"2016","unstructured":"Morgan\u00a0ND et\u00a0al (2016) Curr Treatm Opt Rheumatol 2(1):69\u201384","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"11","key":"699_CR29","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai\u00a0M et\u00a0al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76(11):1897\u20131905","journal-title":"Ann Rheum Dis"},{"key":"699_CR30","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall\u00a0AJ, Bannert\u00a0B, Vonk\u00a0M et\u00a0al (2010) Causes and risk factors for death in systemic sclerosis: a\u00a0study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"699_CR31","doi-asserted-by":"crossref","first-page":"e0153012","DOI":"10.1371\/journal.pone.0153012","volume":"11","author":"G De Luca","year":"2016","unstructured":"De Luca\u00a0G, Bosello\u00a0SL, Gabrielli\u00a0FA et\u00a0al (2016) Prognostic role of ventricular ectopic beats in systemic sclerosis: a prospective cohort study shows ECG indexes predicting the worse outcome. PLoS ONE 11:e153012","journal-title":"PLoS ONE"},{"key":"699_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197112","author":"D Launay","year":"2018","unstructured":"Launay\u00a0D (2018) Plos One. https:\/\/doi.org\/10.1371\/journal.pone.0197112","journal-title":"Plos One"},{"key":"699_CR33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan\u00a0JG, Denton\u00a0CP, Gr\u00fcnig\u00a0E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340\u20131349","journal-title":"Ann Rheum Dis"},{"key":"699_CR34","first-page":"1639","volume":"53","author":"WS Chung","year":"2014","unstructured":"Chung\u00a0WS, Lin\u00a0CL, Sung\u00a0FC et\u00a0al (2014) Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a\u00a0nationwide cohort study. Baillieres Clin Rheumatol 53:1639\u20131645","journal-title":"Baillieres Clin Rheumatol"},{"issue":"5","key":"699_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.160817","volume":"44","author":"MG Lazarroni","year":"2017","unstructured":"Lazarroni\u00a0MG (2017) J\u00a0Rheumatol 44(5):639\u2013647. https:\/\/doi.org\/10.3899\/jrheum.160817","journal-title":"J Rheumatol"},{"key":"699_CR36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/039463200902200303","volume":"22","author":"B Marasini","year":"2009","unstructured":"Marasini\u00a0B, Conciato\u00a0L, Belloli\u00a0L et\u00a0al (2009) Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 22:573\u2013578","journal-title":"Int J Immunopathol Pharmacol"},{"key":"699_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O et al (2017) Ann Rheum Dis 76:1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"699_CR38","first-page":"1906","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton\u00a0CP, Hughes\u00a0M, Gak\u00a0N et\u00a0al (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Baillieres Clin Rheumatol 55:1906\u20131910","journal-title":"Baillieres Clin Rheumatol"},{"key":"699_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208121","author":"M Matucci-Cerinic","year":"2015","unstructured":"Matucci-Cerinic\u00a0M, Krieg\u00a0T, Guillevin\u00a0L et al (2015) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208121","journal-title":"Ann Rheum Dis"},{"key":"699_CR40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0031-1298798","volume":"137","author":"G Riemekasten","year":"2012","unstructured":"Riemekasten\u00a0G, Hoffmann\u00a0U, Sunderk\u00f6tter\u00a0C et\u00a0al (2012) Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr 137:34\u201340","journal-title":"Dtsch Med Wochenschr"},{"issue":"2","key":"699_CR41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","volume":"46","author":"V McLaughlin","year":"2015","unstructured":"McLaughlin\u00a0V, Channick\u00a0RN, Ghofrani\u00a0HA et\u00a0al (2015) Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir\u00a0J 46(2):405\u2013413","journal-title":"Eur Respir J"},{"issue":"9","key":"699_CR42","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie\u00a0N, Barbera\u00a0JA, Frost\u00a0AE et\u00a0al (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N\u00a0Engl J Med 373(9):834\u2013844","journal-title":"N Engl J Med"},{"issue":"3","key":"699_CR43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","volume":"155","author":"JR Klinger","year":"2019","unstructured":"Klinger\u00a0JR et\u00a0al (2019) Chest 155(3):565\u2013586","journal-title":"Chest"},{"key":"699_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317","author":"N Galie","year":"2016","unstructured":"Galie\u00a0N (2016) Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317","journal-title":"Eur Heart J"},{"issue":"9","key":"699_CR45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP (2016) Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir. Med."},{"issue":"supplement 2","key":"699_CR46","first-page":"A169","volume":"78","author":"O Koneva","year":"2019","unstructured":"Koneva\u00a0O (2019) Ann Rheum Dis 78(supplement 2):A169","journal-title":"Ann Rheum Dis"},{"key":"699_CR47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009742.2013.812238","volume":"43","author":"FV de Paoli","year":"2014","unstructured":"de Paoli\u00a0FV, Nielsen\u00a0BD, Rasmussen\u00a0F et\u00a0al (2014) Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 43:342\u2013345","journal-title":"Scand J Rheumatol"},{"key":"699_CR48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ced.12450","volume":"40","author":"FC Moazedi-Fuerst","year":"2015","unstructured":"Moazedi-Fuerst\u00a0FC, Kielhauser\u00a0SM, Bodo\u00a0K et al (2015) Dosage of rituximab in systemic sclerosis: 2\u2011year results of five cases. Clin Exp Dermatol 40:211\u2013212","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"699_CR49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM (2018) N\u00a0Engl J Med 378(1):35\u201347","journal-title":"N Engl J Med"},{"key":"699_CR50","doi-asserted-by":"crossref","first-page":"e000533","DOI":"10.1136\/rmdopen-2017-000533","volume":"4","author":"UA Walker","year":"2018","unstructured":"Walker\u00a0UA, Saketkoo\u00a0LA, Distler\u00a0O (2018) Haematopoietic stem cell transplantation in systemic sclerosis. RMD Open 4:e533","journal-title":"RMD Open"},{"issue":"supplement 2","key":"699_CR51","first-page":"A1206","volume":"78","author":"S Bijnen","year":"2019","unstructured":"Bijnen\u00a0S et al (2019) Predictive factors for treatment related mortality and major adverse events after autologous hematopoietic stem cell transplantation for systemic sclerosis: results of a long term follow-up multi-centre studyS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. Ann Rheum Dis 78(supplement 2):A1206","journal-title":"Ann Rheum Dis"},{"key":"699_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O et\u00a0al (2019) N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"issue":"10038","key":"699_CR53","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D (2016) Lancet 387(10038):2630\u20132640","journal-title":"Lancet"},{"issue":"suppl 2","key":"699_CR54","first-page":"SA202","volume":"78","author":"D Khanna","year":"2019","unstructured":"Khanna\u00a0D (2019) Ann Rheum Dis 78(suppl 2):SA202","journal-title":"Ann Rheum Dis"},{"issue":"supplement 2","key":"699_CR55","first-page":"A106","volume":"78","author":"D Khanna","year":"2019","unstructured":"Khanna\u00a0D et al (2019) Abatacept in early diffuse cutaneous systemic sclerosis\u2014 results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial TRIAL. Ann Rheum Dis 78(supplement 2):A106","journal-title":"Ann Rheum Dis"},{"issue":"supplement 2","key":"699_CR56","first-page":"A167","volume":"78","author":"J Distler","year":"2019","unstructured":"Distler\u00a0J (2019) Ann Rheum Dis 78(supplement 2):A167","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"699_CR57","first-page":"A1216","volume":"78","author":"D Khanna","year":"2019","unstructured":"Khanna\u00a0D (2019) Ann Rheum Dis 78(Suppl 2):A1216","journal-title":"Ann Rheum Dis"},{"issue":"supplement 2","key":"699_CR58","first-page":"A200","volume":"78","author":"N Acharya","year":"2019","unstructured":"Acharya\u00a0N (2019) Ann Rheum Dis 78(supplement 2):A200","journal-title":"Ann Rheum Dis"},{"key":"699_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.3512","author":"R Spiera","year":"2018","unstructured":"Spiera\u00a0R (2018) Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.3512","journal-title":"Ann Rheum Dis"},{"issue":"supplement 2","key":"699_CR60","first-page":"A105","volume":"78","author":"M Spiritovic","year":"2019","unstructured":"Spiritovic\u00a0M et al (2019) Effectivness of specialized hand\/face physical-occupational therapy in patients with systemic sclerosis\u2014preliminary results of a one-year controlled studySTUDY. Ann Rheum Dis 78(supplement 2):A105","journal-title":"Ann Rheum Dis"},{"key":"699_CR61","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1136\/ard.2009.123273","volume":"69","author":"L Krause","year":"2010","unstructured":"Krause\u00a0L, Becker\u00a0MO, Brueckner\u00a0CS et\u00a0al (2010) Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 69:1951\u20131957","journal-title":"Ann Rheum Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-00699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T04:11:00Z","timestamp":1605845460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-00699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-00699-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"21 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Schinke<\/b>: Finanzielle Interessen: Jansen (Kostenerstattung European League Against Rheumatism [EULAR] 2018, 2019) | MSD (Fortbildung TNF\u2011\u03b1 Forum 2019) | Pfizer (Referentenhonorar L\u00fcbecker Rheuma Visite 2018, 2019) | Pfizer (Fortbildung i-FemMe 2018, Reise\u2011\/\u00dcbernachtungskosten) | Celgene (Fortbildung ASV 2017, Reisekosten) | AbbVie (Fortbildung 2017, Reise und Hotel) | UCB (Fortbildung Deutsche Gesellschaft f\u00fcr Rheumatologie [DGRh] 2017, Reise\u2011\/\u00dcbernachtungskosten) | ChemoCentryx (Studie, Reise\/Unterkunft 2017) (kein Bezug zu diesem Artikel). Nichtfinanzielle Interessen: Angestellte Rheumatologin, Universit\u00e4tsklinikum Schleswig-Holstein (UKSH), Campus L\u00fcbeck | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), DGRh, British Society for Immunology (BSI). <b>G.\u00a0Riemekasten<\/b>: Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Roche, Amgen, Novartis, Actelion, GSK, Lilly (kein Bezug zu diesem Artikel). Nichtfinanzielle Interessen: Klinikdirektion, UKSH L\u00fcbeck | Mitgliedschaften: Deutsches Netzwerk f\u00fcr Systemische Sklerodermie (DNSS), European Scleroderma Trials and Research Group (EUSTAR).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}